Electrophysiologic Effects of Growth Hormone Post-Myocardial Infarction

Konstantinos V Stamatis1, Marianthi Kontonika2, Evangelos P Daskalopoulos3

  • 11st Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.

Insights

Growth hormone therapy may improve heart function and reduce arrhythmias after myocardial infarction. Studies suggest it aids in healing and preserves heart muscle, offering potential benefits for heart attack survivors.

Area of Science:

  • Cardiology
  • Endocrinology
  • Molecular Medicine

Background:

  • Myocardial infarction (MI) causes significant electrophysiologic and structural changes, leading to heart failure and sudden cardiac death.
  • The growth hormone/insulin-like growth factor-1 axis plays a crucial role in post-MI cardiac remodeling.
  • Ventricular tachyarrhythmias are a major complication, often arising from fibrosis and altered heart structure.

Purpose of the Study:

  • To review the acute and chronic effects of growth hormone (GH) administration post-MI.
  • To emphasize the electrophysiologic effects of GH therapy in the context of myocardial infarction.
  • To discuss potential mechanisms underlying GH's actions and inform future research.

Main Methods:

  • Review of experimental studies in animal models.
  • Analysis of clinical data on GH administration post-MI.
  • Discussion of hypotheses regarding GH's mechanisms of action.

Main Results:

  • Experimental studies show GH administration attenuates left ventricular dilatation and improves systolic function post-MI.
  • GH treatment demonstrates antiarrhythmic effects and preserves peri-infarct myocardium.
  • Evidence suggests GH influences structural and electrophysiologic remodeling after myocardial infarction.

Conclusions:

  • GH therapy shows promise in mitigating adverse post-MI remodeling and reducing arrhythmia risk.
  • Understanding the precise mechanisms of GH action is crucial for optimizing its therapeutic application.
  • Further research is needed to enhance the translational value of GH therapy for acute myocardial infarction patients.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
307
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
603
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
127
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
253
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
380